Metraipolis › archive › dc_3785b8963006

Theranostic application of radiolabeled HER2-targeting single-domain antibodies (RAD202) in preclinical setting — Europe PMC PMID:41188605

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41188605
DOI
10.1038/s41598-[numero omesso]-w
License (as archived)
solo-consultazione
Archived
2026-11-08T19:17:17.533Z
SHA-256 of the archived text
cdecffd8f9c60f0cd7b703ae99fb570f2d2168fe9bff7309a8e2a0935d9e657c
Stable URL of this page
https://metraipolis.com/documento/dc_3785b8963006

How to cite

Theranostic application of radiolabeled HER2-targeting single-domain antibodies (RAD202) in preclinical setting — Europe PMC PMID:41188605 — Europe PMC (en), https://europepmc.org/article/MED/41188605 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3785b8963006 (Metraipolis archive dc_3785b8963006, sha256 cdecffd8f9c60f0cd7b703ae99fb570f2d2168fe9bff7309a8e2a0935d9e657c)
BibTeX
@misc{dc3785b8963006,
  title = {Theranostic application of radiolabeled HER2-targeting single-domain antibodies (RAD202) in preclinical setting — Europe PMC PMID:41188605},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41188605},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3785b8963006; sha256 cdecffd8f9c60f0cd7b703ae99fb570f2d2168fe9bff7309a8e2a0935d9e657c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41188605. Agents can read the archived copy with the MCP tool read_document.